research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
Search
for
Sort by
Research
180-210 / 1000+ results 
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Overview Of Alopecia Areata For Managed Care And Payer Stakeholders In The United States
Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
research Systemic Immunotherapies
Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research A Single-Center Retrospective Study Evaluating the Efficacy of Intravenous Methylprednisolone Pulse Therapy for 113 Patients With Alopecia Areata
Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
research Baricitinib For Alopecia Areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Alopecia Areata in Children: An Overview of Clinical Features and Recent Treatment Options
New treatments for child hair loss due to immune issues are effective but not yet officially approved.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Analyzing the Role of Tofacitinib in Treatment of Alopecia Areata: A Retrospective Analysis from a Tertiary Care Center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
research The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Common Causes of Hair Loss
Hair loss can be caused by hormones, illness, autoimmune disorders, or vitamin deficiencies, and treatments vary depending on the type.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research JAMA Dermatology: The Year in Review, 2021
In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research 22-Year-Old Male with Several Discrete Patches of Hair Loss
A 22-year-old man has alopecia areata, an autoimmune hair loss condition, with various treatments available.
research Reply to Early Onset Effluvium Secondary to COVID-19 and Body-Hair Effluvium
COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.
research Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata
Tofacitinib, a hair regrowth treatment, may worsen acne.
research The Changing Landscape of Managing Hair Loss: A 30-Year Perspective
There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.
research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research Alopecia Areata: Multifactorial Disease Involving Genetic, Environmental, and Autoimmune Factors
Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.
research Successful Treatment of Alopecia Totalis with Tofacitinib in a Danish Patient
A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.